Abstract
One of the hallmarks of the global pandemic of coronavirus disease 2019 (COVID-19) is that it targets the immune system by producing inflammatory cytokines. COVID-19 has expedited investigations on numerous therapeutics to fight the disease-causing virus SARS-CoV-2, some without well-established safety or efficacy data. The severity of the disease depends on a number of factors, including genetic background and preexisting conditions. The difference in the genetic makeup makes everyone unique and the understanding of the COVID-19 cure arduous. To dampen these inflammatory markers and to understand the viral disease dynamics, accounting for genetic variability, a combinational three-way approach involving bioinformatics, nutrigenomics, and pharmacogenomics will give answers to many unanswered questions involving patient care. A futuristic approach to prevention and cure calls for continuous research with practice and training provision to the right group, accompanied with the awareness enhancing its utility.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A, Chidambaram A, Gerrard B, Baird L, Stauffer D, Peiffer A, Rattner A, Smallwood P, Li Y, Anderson KL, Lewis RA, Nathans J, Leppert M, Dean M, Lupski JR (1997) A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet 15(3):236–246. https://doi.org/10.1038/ng0397-236
Bakelmun I (2020) Global health 50/50.
Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H, Zhang Y, Dorgham K, Philippot Q, Rosain J, Béziat V, Manry J, Shaw E, Haljasmägi L, Peterson P, Lorenzo L, Bizien L, Trouillet-Assant S, Dobbs K, de Jesus AA et al (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370(6515):eabd4585. https://doi.org/10.1126/science.abd4585
Beck MA, Esworthy RS, Ho Y, Chu F (1998) Glutathione peroxidase protects mice from viral-induced myocarditis. FASEB J 12(12):1143–1149. https://doi.org/10.1096/fasebj.12.12.1143
Beck MA, Williams-Toone D, Levander OA (2003) Coxsackievirus B3-resistant mice become susceptible in Se/vitamin E deficiency. Free Radic Biol Med 34(10):1263–1270
Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC-C, Edwards KM, Gandhi R, Gallagher J, Muller WJ, O’Horo JC, Shmuel S, Hassan Murad M, Mustafa RA, Sultan S, Falck-Ytter Y (2020) Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 infection. https://www.idsociety.org/COVID19guidelines
Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, Wen F, Huang X, Ning G, Wang W (2020) Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov 6:11–11. eCollection 2020. https://doi.org/10.1038/s41421-020-0147-1
Cheng K, Wei M, Shen H, Wu C, Chen D, Xiong W (2020) Clinical characteristics of 463 patients with common and severe type coronavirus disease. Shanghai Med J:1–15. (In Chinese)
CYP2C8: The Pharmacogene Variation (PharmVar) Consortium (2020). https://www.pharmvar.org/gene/CYP2C8
CYP2D6: The Pharmacogene Variation (PharmVar) Consortium (2020). https://www.pharmvar.org/gene/CYP2D6
CYP3A4: The Pharmacogene Variation (PharmVar) Consortium. (2020). https://www.pharmvar.org/gene/CYP3A
Deng L, Zeng Q, Wang M, Cheng A, Jia R, Chen S, Zhu D, Liu M, Yang Q, Wu Y, Zhao X, Zhang S, Liu Y, Yu Y, Zhang L, Chen X (2018) Suppression of NF-κB Activity: a viral immune evasion mechanism. Viruses 10(8):409. https://doi.org/10.3390/v10080409
Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 3(7):797–801. https://doi.org/10.1038/nm0797-797
FDA (2020) In Gilead Sciences (Ed.), Fact sheet for health care providers: emergency use authorization (EUA) of remdesivir (GS-5734™), and full EUA prescribing information. 2020. http://www.fda.gov/. Accessed 24 Jul 2020
FDA Letter to Gilead Sciences, Inc (2020) Gilead Sciences. Gilead’s investigational antiviral remdesivir receives US Food and Drug Administration emergency use authorization for the treatment of COVID-19 [media release]. 1 May 2020. http://www.gilead.com. https://www.fda.gov/media/137564/download
Fohner AE, Sparreboom A, Altman RB, Klein TE (2017) PharmGKB summary: macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics 27(4):164–167. https://doi.org/10.1097/FPC.0000000000000270
Gao Y, Li T, Han M, Li X, Wu D, Xu Y, Zhu Y, Liu Y, Wang X, Wang L (2020) Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 92(7):791–796. https://doi.org/10.1002/jmv.25770
Ghosh D, Skinner MA, Laing WA (2007) Pharmacogenomics and nutrigenomics: synergies and differences. Eur J Clin Nutr 61(5):567–574
Guillin OM, Vindry C, Ohlmann T, Chavatte L (2019) Selenium, selenoproteins and viral infection. Nutrients 11(9):2101. https://doi.org/10.3390/nu11092101
Guisado-Vasco P, Cano-Megías M, Rodríguez-López M, de Luna-Boquera IM, Carnevali-Ruiz D, Immunosuppressants Against COVID-19, Working Team (2020) COVID-19 and metabolic syndrome: NF-κB activation. Crossroads. Trends Endocrinol Metab 31(11):802–803. https://doi.org/10.1016/j.tem.2020.08.004
He XJ, Zhao LM, Qiu F, Sun YX, Li-Ling J (2009) Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. Pharmacol Rep 61(5):843–850
Ivanov V, Cha J, Ivanova S, Kalinovsky T, Roomi M, Rath M, Niedzwiecki A (2008) Essential nutrients suppress inflammation by modulating key inflammatory gene expression. Int J Mol Med 22(6):731–741. https://doi.org/10.3892/ijmm_00000079
Kolilekas L, Loverdos K, Giannakaki S, Vlassi L, Levounets A, Zervas E, Gaga M (2020) Can steroids reverse the severe COVID-19 induced “cytokine storm”? J Med Virol 92(11):2866–2869. https://doi.org/10.1002/jmv.26165
Lebwohl B, Sanders DS, Green PHR (2018) Coeliac disease. Lancet (London, England) 391(10115):70–81
Lingeswaran M, Goyal T, Ghosh R, Suri S, Mitra P, Misra S, Sharma P (2020) Inflammation, immunity and immunogenetics in COVID-19: a narrative review. Indian J Clin Biochem 35(3):260–273. https://doi.org/10.1007/s12291-020-00897-3
McLachlan CS (2020) The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms. Clin Hypertension 26(1):14. https://doi.org/10.1186/s40885-020-00147-x
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, HLH Across Speciality Collaboration, UK (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England) 395(10229):1033–1034
Muñoz-Fontela C, Dowling WE, Funnell SGP, Gsell PS, Riveros-Balta AX, Albrecht RA, Andersen H, Baric RS, Carroll MW, Cavaleri M, Qin C, Crozier I, Dallmeier K, de Waal L, de Wit E, Delang L, Dohm E, Duprex WP, Falzarano D et al (2020) Animal models for COVID-19. Nature 586(7830):509–515. https://doi.org/10.1038/s41586-020-2787-6
Okamoto H, Ichikawa N (2021) The pivotal role of the angiotensin-II–NF-κB axis in the development of COVID-19 pathophysiology. Hypertens Res 44(1):126–128. https://doi.org/10.1038/s41440-020-00560-7
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS (2020) Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 71(15):762–768. https://doi.org/10.1093/cid/ciaa248
Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse A, DeHovitz J, Blog DS, Hutton B, Holtgrave DR, Zucker HA (2020) Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 323(24):2493–2502. https://doi.org/10.1001/jama.2020.8630
Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB, Dörje F, Fromm MF, König J (2007) The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 35(5):779–786
Shah A (2020) We are what we eat-nutrition, Immunity and Virus. https://0901.nccdn.net/4_2/000/000/076/de9/CV-Network-Vol-19-No-1-March-2020.pdf
Sharma G, Volgman AS, Michos ED (2020) Sex differences in mortality from COVID-19 pandemic: are men vulnerable and women protected? JACC Case Rep 2(9):1407–1410. https://doi.org/10.1016/j.jaccas.2020.04.027
Swanson A (2020) COVID-19: genetic research and a novel pathway. https://nutritiongenome.com/genetic-research-and-a-novel-pathway-for-covid-19/
Takahashi T, Luzum JA, Nicol MR, Jacobson PA (2020) Pharmacogenomics of COVID-19 therapies. NPJ Genom Med 5(1):35. https://doi.org/10.1038/s41525-020-00143-y
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP (2020) The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 20(6):363–374. https://doi.org/10.1038/s41577-020-0311-8
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W et al (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180(7):934–943. https://doi.org/10.1001/jamainternmed.2020.0994
Xiang T, Liu J, Xu F, Cheng N, Liu Y, Qian K (2020) Analysis of clinical characteristics of 49 patients with novel coronavirus pneumonia in Jiangxi province. Chin J Respir Crit Care Med
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8(4):420–422
Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, Deng G (2020) Association of inflammatory markers with the severity of COVID-19: a meta-analysis. Int J Infect Dis 96:467–474. https://doi.org/10.1016/j.ijid.2020.05.055
Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabli IKD, Hodeib S, Korol C, Rosain J, Bilguvar K, Ye J, Bolze A, Bigio B, Yang R, Arias AA, Zhou Q, Zhang Y et al (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370(6515):eabd4570. https://doi.org/10.1126/science.abd4570
Acknowledgements
Infrastructural support was provided by the California State University, Los Angeles.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive licence to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Shah, A.K., Momand, J. (2021). Dampening of Inflammatory Markers and Understanding COVID-19 Viral Disease Development: A Combinatorial Approach. In: Sobti, R.C., Dhalla, N.S., Watanabe, M., Sobti, A. (eds) Delineating Health and Health System: Mechanistic Insights into Covid 19 Complications. Springer, Singapore. https://doi.org/10.1007/978-981-16-5105-2_16
Download citation
DOI: https://doi.org/10.1007/978-981-16-5105-2_16
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-5104-5
Online ISBN: 978-981-16-5105-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)